Related Experiment Video
Updated: Jul 14, 2025

Quantifying Spontaneous Ca2+ Fluxes and their Downstream Effects in Primary Mouse Midbrain Neurons
Published on: September 9, 2020
GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics
Davide Zecchin1, Nicole Knöpfel2, Anna K Gluck3
1Mosaicism and Precision Medicine Laboratory, Francis Crick Institute, London, United Kingdom; Genetics and Genomic Medicine, UCL GOS Institute of Child Health, London, United Kingdom.
Abstract:
Mosaic variants in genes GNAQ or GNA11 lead to a spectrum of vascular and pigmentary diseases including Sturge-Weber syndrome, in which progressive postnatal neurological deterioration led us to seek biologically targeted therapeutics. Using two cellular models, we find that disease-causing GNAQ/11 variants hyperactivate constitutive and G-protein coupled receptor ligand-induced intracellular calcium signaling in endothelial cells. We go on to show that the aberrant ligand-activated intracellular calcium signal is fueled by extracellular calcium influx through calcium-release-activated channels. Treatment with targeted small interfering RNAs designed to silence the variant allele preferentially corrects both the constitutive and ligand-activated calcium signaling, whereas treatment with a calcium-release-activated channel inhibitor rescues the ligand-activated signal. This work identifies hyperactivated calcium signaling as the primary biological abnormality in GNAQ/11 mosaicism and paves the way for clinical trials with genetic or small molecule therapies.
Insights
Mosaic variants in GNAQ/11 genes cause diseases like Sturge-Weber syndrome. This study found that hyperactivated calcium signaling is the key issue, suggesting targeted therapies for these vascular and pigmentary disorders.
Area of Science:
- Genetics and Molecular Biology
- Cellular Biology
- Vascular Biology
Background:
- Mosaic variants in GNAQ or GNA11 genes are associated with vascular and pigmentary diseases, including Sturge-Weber syndrome.
- Progressive neurological deterioration in Sturge-Weber syndrome necessitates the development of targeted therapeutics.
Purpose of the Study:
- To investigate the underlying biological mechanisms of GNAQ/11 mosaicism.
- To identify potential therapeutic targets for GNAQ/11-related disorders.
Main Methods:
- Utilized two cellular models to study GNAQ/11 variants.
- Employed small interfering RNAs (siRNAs) to silence variant alleles.
- Administered calcium-release-activated channel inhibitors.
Main Results:
- Disease-causing GNAQ/11 variants lead to hyperactivation of intracellular calcium signaling in endothelial cells.
- This aberrant signaling is sustained by extracellular calcium influx via calcium-release-activated channels.
- siRNA treatment corrected both constitutive and ligand-activated calcium signaling, while channel inhibitors only rescued ligand-activated signaling.
Conclusions:
- Hyperactivated calcium signaling is identified as the primary abnormality in GNAQ/11 mosaicism.
- This finding supports the potential for genetic or small molecule therapies.
- The study lays the groundwork for future clinical trials targeting these pathways.
More Related Videos
13:40Live Cell Calcium Imaging Combined with siRNA Mediated Gene Silencing Identifies Ca2+ Leak Channels in the ER Membrane and their Regulatory Mechanisms
Published on: July 7, 2011
08:46Forward Genetic Screen Using Transgenic Calcium Reporter Aequorin to Identify Novel Targets in Calcium Signaling
Published on: August 1, 2020
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Abnormal Proliferation
Ligand-Gated Ion Channel Receptor: Gating Mechanism